Early buyers will receive 10% customization on this report.
Industry Dynamics:
This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer.
Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.
North America is expected to account for the largest share of the transfection reagents market, followed by Europe and Asia-Pacific. The largest share can be attributed to the increase in bio-based drug research, increase in demand for protein therapeutics, and increasing investment for development of biologics in the country.
The Asia-Pacific market is slated to grow at the highest CAGR during the forecast period and serve as a major revenue pocket for companies offering transfection reagents and equipment.
Some of the prominent players in the transfection reagents market include Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands). Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc. (U.S.).
Target Audience:
• Biopharmaceutical companies
• Biotechnology companies
• Transfection equipment, reagent, and kit manufacturing companies
• Suppliers and distributors of transfection reagents
• Research institutes
• Academic centers
• Venture capitalists
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: